Additionally, Ghosh et al. demonstrated that inactivating HIF-2α with the second-generation allosteric inhibitor MK-6482, a FDA approved drug for renal carcinoma, attenuated polycythemia and PH in VhlR200W mice, Irp1-KO mice, and double mutant VhlR200W;Irp1-KO mice with PH. Here, ACO1 is linked to renal carcinoma.